PENNYSESurgical & Medical Instruments & ApparatusUS GAAP · USD

Penumbra Inc

Penumbra is a U.S.-based medical device company focused on thrombectomy and related interventional therapies for removing blood clots from the body. Its portfolio spans products used in ischemic stroke, pulmonary embolism, acute limb ischemia, embolization, and vascular access, and it sells through direct commercial teams and distributors across the United States and international markets.

Kysy yhtiöstä
Liikevaihto1 404milj. USD
+17,5 %v/v
Liikevoitto (EBIT)189milj. USD
+1 939,5 %v/v
EBIT-marginaali13,5%
+12,7 %-yks.v/v
Nettotulos178milj. USD
+1 168,1 %v/v
Vapaa kassavirta175milj. USD
+18,8 %v/v

Tilikausi 2025 · muutos edellisvuodesta

Kehitys 2020–2025

−50005001 0001 500milj. USD2020: 560 milj. USD2020: EBIT −39 milj. USD20202021: 748 milj. USD2021: EBIT −7,5 milj. USD20212022: 847 milj. USD2022: EBIT 6,1 milj. USD20222023: 1 059 milj. USD2023: EBIT 74 milj. USD20232024: 1 195 milj. USD2024: EBIT 9,3 milj. USD20242025: 1 404 milj. USD2025: EBIT 189 milj. USD20251 404189
LiikevaihtoLiikevoitto (EBIT)
Kysy Clarifolta: Penumbra Inc

Liiketoiminta

Osuus liikevaihdosta
Thrombectomy systems55 %

Devices and systems used to remove blood clots in stroke, PE, and limb ischemia.

Neurovascular products20 %

Products used by specialists treating ischemic stroke and other neurovascular conditions.

Vascular access and embolization15 %

Tools for accessing vessels and treating vascular abnormalities or bleeding.

Other interventional products10 %

Adjunct products and newer offerings supporting the broader interventional portfolio.

Tuotteet

Raportoitu · osuus liikevaihdosta
67,5%32,5%FY2025100 %
  • Thrombectomy67,5 %
  • Embolization32,5 %

Lähde: 10-K FY2025, yhtiön tuotelinjoittain raportoima liikevaihto (SEC XBRL). Osuudet on laskettu näytetyistä riveistä ja ne summautuvat 100 %:iin.

Asiakkaat

Penumbra sells primarily to hospitals and healthcare systems that perform high-acuity interventional procedures. The end users are specialist physicians such as interventional neuroradiologists, neurosurgeons, interventional neurologists, interventional radiologists, interventional cardiologists, and vascular surgeons who choose these devices based on clinical performance, ease of use, and workflow efficiency.

Hospitals and health systems

Buy devices for use in acute care and interventional suites where clot removal procedures are performed.

Specialist physicians

Interventional neuroradiologists, neurologists, radiologists, cardiologists, and surgeons who use the products in procedures.

International distributors

Buy and resell products in select markets where Penumbra does not sell entirely through direct teams.

Healthcare providers in emerging end markets

Providers adopting thrombectomy and embolization therapies as clinical evidence and training expand.

Strategia

Penumbra’s strategy centers on expanding its thrombectomy and interventional portfolio through product development, clinical evidence, and commercial expansion. It also continues to invest in manufacturing capacity, inventory, and international reach so it can support broader adoption of its devices and launch new products across target end markets.

Expand the thrombectomy portfolioKeskipitkä aikaväli

New and improved devices support adoption in stroke, PE, and limb ischemia.

Build clinical evidence and physician adoptionKeskipitkä aikaväli

Specialist physicians need proof of efficacy and training before changing practice.

Expand manufacturing and supply capacityLyhyt aikaväli

Device demand requires reliable production, inventory, and facility footprint.

Grow international commercializationKeskipitkä aikaväli

Broader geographic reach diversifies demand and extends the installed base.

Maantiede

Q1/2026

Penumbra generates most of its revenue in the United States, with the balance coming from international markets. It sells directly in the U.S., most of Europe, Canada, Australia, and Singapore, and uses distributors in select countries, so its operating footprint is tied to both hospital adoption and regulatory access across multiple healthcare systems.

USA79 %
Other countries (US filing)21 %

Osuus liikevaihdosta, jonka yhtiö raportoi maantieteellisesti.

Riskit

Penumbra faces competitive, regulatory, and execution risks typical of medical device companies, including reimbursement pressure, product adoption hurdles, and dependence on specialist physicians. Company-specific risks include supplier concentration, IT and ERP disruption, and uncertainty around the proposed Boston Scientific acquisition, all of which could affect operations and customer continuity.

Järjestetty vakavuuden mukaan
MatalaKohtalainenKorkeaMatalaKohtalainenKorkeaVaikutus →Todennäköisyys →Supplier concentration and component shortages1Reimbursement and pricing pressure2Competitive intensity3Acquisition uncertainty4IT and ERP implementation disruption5
Vaikutus on riskin vakavuus ja todennäköisyys sen toteutumisen todennäköisyys lähivuosina, molemmat arvioitu yhtiön raporttien perusteella. Numerot vastaavat listaa.
  1. Supplier concentration and component shortagesVaikutus: KorkeaTodennäköisyys: Kohtalainen

    Many materials and components come from a limited number of suppliers, with little guaranteed supply.

    Kohdistuu: Manufacturing continuity and product availability

  2. Reimbursement and pricing pressureVaikutus: KorkeaTodennäköisyys: Kohtalainen

    Hospitals and payors may limit payment for medical devices through cost-control programs.

    Kohdistuu: Procedure adoption and realized selling prices

  3. Competitive intensityVaikutus: KorkeaTodennäköisyys: Kohtalainen

    Large rivals have broader product lines, deeper relationships, and more resources.

    Kohdistuu: Market share and physician adoption

  4. Acquisition uncertaintyVaikutus: KorkeaTodennäköisyys: Kohtalainen

    Pending transaction uncertainty can affect customers, employees, and business execution.

    Kohdistuu: Commercial continuity and strategic flexibility

  5. IT and ERP implementation disruptionVaikutus: KeskitasoTodennäköisyys: Kohtalainen

    System changes can interrupt order tracking, shipping, supply chain, and financial data aggregation.

    Kohdistuu: Operations and reporting reliability

Kysy Clarifolta: Penumbra Inc

Kirjanpito

Harkinnanvaraiset erät
Revenue recognition for product sales

Device revenue depends on shipment timing, returns, and contract terms.

Vaikutus: Can shift quarterly revenue and comparability

Inventory and manufacturing estimates

Production planning and inventory levels affect cost of sales and obsolescence risk.

Vaikutus: Affects gross margin and working capital

Impairment and exit charges

The company recorded charges when exiting immersive healthcare.

Vaikutus: Can materially affect operating income in the period recognized

ERP and internal control changes

System implementations can affect order tracking and financial data aggregation.

Vaikutus: May influence cut-off, controls, and reporting reliability

Samankaltaisia listattuja yhtiöitä

Julkisesti listattuja yhtiöitä, joilla on samankaltainen liiketoiminta.

LivaNova PLC

LIVN · Electromedical & Electrotherapeutic Apparatus

Boston Scientific Corporation

BSX · Surgical & Medical Instruments & Apparatus

Globus Medical, Inc

GMED · Surgical & Medical Instruments & Apparatus

enVVeno Medical Corp

NVNO · Surgical & Medical Instruments & Apparatus

TriSalus Life Sciences, Inc.

TLSIW · Surgical & Medical Instruments & Apparatus

ENvue Medical, Inc.

FEED · Orthopedic, Prosthetic & Surgical Appliances & Supplies

Päivitetty: 24.9.2026

Penumbra Inc (PEN) liikevaihto, tulos ja tunnusluvut 2025 – Clarifo